Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.92 USD | +1.43% |
|
-0.52% | -43.34% |
Jun. 11 | Exact Sciences Seeks Acquisitions | CI |
Jun. 11 | Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.34% | 7.74B | |
+10.68% | 3.66B | |
-1.60% | 2.24B | |
-22.96% | 1.98B | |
-22.17% | 1.64B | |
+5.19% | 915M | |
+17.25% | 733M | |
-6.99% | 710M | |
-37.14% | 454M | |
-2.29% | 287M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023